Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 1, 2013, Pages 19-28

  Hiligsmann, Mickaël ^a   Boonen, Annelies ^a   Dirksen, Carmen D ^a   Sedrine, Wafa Ben ^b   Reginster, Jean Yves ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

cost effectiveness; denosumab; osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873903305     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.76     Document Type: Article

References (51)

1. Kanis JA, Odén A, McCloskey EV, Johansson H, Wahl DA, Cooper C; IOF Working Group on Epidemiology and Quality of Life. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos. Int. 23(9), 2239-2256 (2012).
2. Haentjens P, Magaziner J, Colón-Emeric CS et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann. Intern. Med. 152(6), 380-390 (2010).
3. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos. Int. 16(5), 447-455 (2005).
4. Johnell O, Kanis JA, Odén A et al. Mortality after osteoporotic fractures. Osteoporos. Int. 15(1), 38-42 (2004).
5. Ström O, Borgström F, Kanis JA et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 6(1-2), 59-155 (2011).
6. Reginster JY. Treatment of postmenopausal osteoporosis. BMJ 330(7496), 859-860 (2005).
7. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin. Pharmacother. 10(14), 2303-2315 (2009).
8. Siris ES, Selby PL, Saag KG, Borgström F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med. 122(Suppl. 2), S3-S13 (2009).
9. Carnevale V, Nieddu L, Romagnoli E et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos. Int. 17(3), 478-483 (2006).
10. Liel Y, Castel H, Bonneh DY. Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low-impact fractures. Osteoporos. Int. 14(6), 490-495 (2003).
11. Rabenda V, Vanoverloop J, Fabri V et al. Low incidence of anti-osteoporosis treatment after hip fracture. J. Bone Joint Surg. Am. 90(10), 2142-2148 (2008).
12. Curtis JR, Yun H, Lange JL et al. Does medication adherence itself confer fracture protection? an investigation of the healthy adherer effect in observational data. Arthritis Care Res. (Hoboken) 64(12), 1855-1863 (2012).
13. Hiligsmann M, Boonen A, Rabenda V, Reginster JY The importance of integrat ing medication adherence into pharmaco-economic analyses: the example of osteoporosis. Expert Rev. Pharmacoecon. Outcomes Res. 12(2), 159-166 (2012).
14. Hiligsmann M, McGowan B, Bennett K, Barry M, Reginster JY The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health 15(5), 604-612 (2012).
15. Hiligsmann M, Rabenda V, Bruyère O, Reginster JY The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96(2), 170-177 (2010).
16. Cummings SR, San Martin J, McClung MR et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756-765 (2009).
17. Jönsson B, Ström O, Eisman JA et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos. Int. 22(3), 967-982 (2011).
18. Freemantle N, Satram-Hoang S, Tang ET et al.; DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos. Int. 23(1), 317-326 (2012).
19. Kendler DL, McClung MR, Freemantle N et al.; DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos. Int. 22(6), 1725-1735 (2011).
20. Drummond M, Sculpher M, O'Brien B, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, New York, NY, USA (2007).
21. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313(7052), 275-283 (1996).
22. Hiligsmann M, Reginster J. Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Value Health 13, A309-A310 (2010).
23. Hiligsmann M, Reginster J. Cost-effectiveness of denosumab compared with generic alendronate in the treatment of postmenopausal osteoporotic women. Osteoporosis Int. 22, S112 (2011).
24. Hiligsmann M, Reginster J. Cost-effectiveness of denosumab compared with oral bisphosphonates in the treatment of postmenopausal osteoporotic women. Osteoporosis Int. 21, S30 (2010).
25. Hiligsmann M, Reginster J. Cost-utility of denosumab for the treatment of postmenopausal osteoporotic women. Osteoporosis Int. 20, S16 (2009).
26. Ström O, Macarios D, Badamgarav E, Borgstrom F, Tosteson A, Kanis J. A UK denosumab cost-effectiveness model incorporating FRAX and Adherence. J. Bone Miner. Res. 24, S141 (2009).
27. Hiligsmann M, Reginster JY Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 47(1), 34-40 (2010).
28. Hiligsmann M, Reginster JY Cost-effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29(10), 895-911 (2011).
29. Scotland G, Waugh N, Royle P, McNamee P, Henderson R, Hollick R. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics 29(11), 951-961 (2011).
30. Ström O, Macarios D, Badamgarav E et al. Cost-effectiveness model for denosumab incorporating FRAX and adherence in a UK Setting. Osteoporosis Int. 20, S20 (2009).
31. Davies A, Compston J, Ferguson S, McCloskey E, Shearer A, Taylor A. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Scotland. Value Health 14, A310 (2011).
32. Parthan A, Defin M, Yurgin N, Huang J, Taylor D. Cost-effectiveness of denosumab versus oral bisphosphonates in the Unites States for post-menopausal osteoporosis. Value Health 15, A38 (2012).
33. Jiang Y, Hay J. The cost-effectiveness of denosumab for the prevention of osteoporotic fractures in the setting of the Unites States. Value Health 15, A38 (2012).
34. Beaubrun A, Daugherty J. Cost-utility analysis of denosumab versus raloxifene for treating osteoporosis in post-menopausal women in the United States. Value Health 14, A129 (2012).
35. Darba J, Kaskens L, Sorio F. Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Value Health 14, A311 (2011).
36. Cristino J, Canhão H, Perelman J, Santos C, Pereira J. Cost-utility analysis of denosumab versus standard care in the treatment of post-menopausal osteoporosis in Portugal. Value Health 14, A128 (2011).
37. Athanasakis K, Karampli E, Hollandezos M et al. A cost-effectiveness analysis of denosumab for the treatment of post-menopausal osteoporosis in Greece. Value Health 14, A138 (2011).
38. Waugh N, Royle P, Scotland G, Henderson R, Hollick R, McNamee P. Denosumab for the prevention of osteoporotic fractures in postmenopausal women. Health Technol Assess. 15(Suppl. 1), 51-59 (2011).
39. Ström O, Borgström F, Sen SS et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos. Int. 18(8), 1047-1061 (2007).
40. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B et al.; National Osteoporosis Foundation Guide Committee. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos. Int. 19(4), 437-447 (2008).
41. Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12(5), 687-696 (2009).
42. Zethraeus N, Borgström F, Ström O, Kanis JA, Jönsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-A review of the literature and a reference model. Osteoporos. Int. 18(1), 9-23 (2007).
43. Drummond M, Barbieri M, Cook J et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12(4), 409-418 (2009).
44. Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos. Int. 22(10), 2565-2573 (2011).
45. McClung M, Boonen S, Törring O et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J. Bone Miner. Res. 27(1), 211-218 (2011).
46. Boonen S, Adachi JD, Man Z et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J. Clin. Endocrinol. Metab. 96(6), 1727-1736 (2011).
47. Cranney A, Guyatt G, Griffth L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23(4), 570-578 (2002).
48. Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96(4), 972-980 (2011).
49. Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information: combined and uneven development. Med. Decis. Making 28(1), 21-32 (2008).
50. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. JAMA 287(21), 2809-2812 (2002).
51. Fleurence RL, Spackman DE, Hollenbeak C. Does the funding source infuence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis. Pharmacoeconomics 28(4), 295-306 (2010).